W. Chiang

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.

J. Sosman, I. Puzanov, A. Santoro, 2012 .

Reply to R. Bhargava et al and F.A. Greco.

N. Laver, J. S. Nystrom, W. Chiang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

withrespecttogeneexpressionprofiling(GEP)anditsabilitytodefine thecelloforiginincancersofunknown/uncertainorigin,asdescribed

N. Laver, J. S. Nystrom, W. Chiang, 2013 .

Cancer of unknown primary: from immunohistochemistry to gene expression profiling.

N. Laver, J. S. Nystrom, W. Chiang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.

J. Sosman, I. Puzanov, A. Adjei, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.